Bridging the gap between Nature and Pharmaceutical
Halucenex is a veteran-focused psychedelics
life sciences company.
The treatment of mental illness in Canada continues to be an underserviced component of the Canadian healthcare system. In any given year, 1 in 5 Canadians experiences a mental illness or addiction problem. By the time Canadians reach 40 years of age, 1 in 2 will have experienced mental illness. These high rates of mental illness and addiction, left untreated, result in disastrously high morbidity rates, especially among Canada’s more vulnerable communities. This increase in morbidity exacerbates Canada’s rates of preventable premature mortality. The economic burden of mental illness in Canada is estimated at $51 billion per year. This includes health care costs, lost productivity, and reductions in health-related quality of life.
There exist at present many highly effective psychotherapeutic treatments for mental illness using a combination of skilled therapists, support groups and medication. However there is limited, timely access to these resources in a manner coinciding with the patient’s treatment needs. Too often, patients can only access one of the aforementioned therapies which leave them with less-than-satisfactory results. This applies especially for patients with drug-resistant conditions for whom traditional medications are often ineffective or trigger adverse side-effects. Patients have very little flexibility in choosing mental health services that work for them.